Marc Hilmi

After almost 1 year @MSKCancerCenter @CpcrMsk 🚀 Honored to present at #AACRpan25 uncovering mechanisms of resistance & response on the POLAR trial. Exciting 2nd year ahead! @CentralParkWMD @EileenMOReilly @ciacobu @jmsongmd @CatherineaOC @MichaelMayMD #PancreaticCancer

🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

That Phase 3 overall survival data is in second line #PancreaticCancer which makes the numbers even more astounding. I cannot recall any other example in pancreatic cancer when OS in a Phase 3 trial basically doubled over existing standard of care. statnews.com/2026/04/13/rev…

🎯 Early findings show potential in KRAS pG12D Setidegrasib, a first-in-class targeted protein degrader, showed antitumor activity in #NSCLC (ORR 36%) and #pancreaticcancer (ORR 24%). 🩺 Wungki Park, MD (@CentralParkWMD); Jonathan W. Goldman, MD | @NEJM ascopost.com/news/april-202…

New in the April 1 issue from the Cancer Research special series: Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer doi.org/10.1158/0008-5… @arnavmehta3 @centralparkwmd @EileenMOReilly @ciacobu @dana_peer #OpenAccess

Top #GICancer Oncologists for Q1 2026, curated by @Larvol CLIN based on most viewed 𝕏 posts. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ClinicalTrials #GastrointestinalCancer #GICSM | @CentralParkWMD | @DraMartinezLago | @ArndtVogel | @DaisukeKotani | @YannickBuccella | @SyedAAhmad5 | @Erman_Akkus | @GIMedOnc | @Aiims1742 | @MarioBalsaMD

In a @NEJM editorial, Department of Medicine Chair @DebSchrag reflected on 30 years of incredible progress in #coloncancer treatment and identified opportunities to harness insights from biomarker testing to customize therapies that reduce side effects. @MSKCancerCenter 📖 bit.ly/4clZWoH

New @NatureMedicine paper from @EileenMOReilly Quemliclustat (CD73 antagonist) and chemotherapy with or without zimberelimab (anti-PD1) in metastatic #PancreaticCancer: a randomized phase 1 trial nature.com/articles/s4159… The concept of a traditional “phase 1” has changed.

On National Doctors’ Day 2026, a toast to Jay’s brilliant oncologist @eileenmoreilly & to superb @MSKCancerCenter pancreas teams past, present, & future. Thanks & gratitude to you, healers all! 🥂

Thank you @ArndtVogel for sharing. This was the Episode II. The first mechanistic work linking immunogenicity in HRD PC is at @biorxivpreprint ⚔️The Episode I: The Origin of Neoantigen 🧬(biorxiv.org/content/10.648…) @xrtGenomics ⚔️The Episode III: Invigorating Tumor Infiltrated Expandable (#TIE) TCR 💉work led by ✨@MarcHilmi 💫 @schoenfeld_j 🌟 @MckerrowWilson 🌞@bengrbm will be at #AACR26 in San Diego. 4/22 9am-12pm Poster Section 51 Board Number: 13 Abstract: LB423 Looking forward to extending the impact! #PrecisionImmunotherapy @EileenMOReilly @ciacobu @ldiaz1971 @TheVinodLab @CpcrMsk @MuschenLab @BWFUND

Thank you @oncodaily for sharing. This was the Episode II. The first mechanistic work linking immunogenicity in HRD PC is at @biorxivpreprint ⚔️The Episode I: The Origin of Neoantigen 🧬(biorxiv.org/content/10.648…) @xrtGenomics ⚔️The Episode III: Invigorating Tumor Infiltrated Expandable (#TIE) TCR 💉work led by ✨@MarcHilmi 💫 @schoenfeld_j 🌟@MckerrowWilson 🌞@bengrbm will be at #AACR26 in San Diego. 4/22 9am-12pm Poster Section 51 Board Number: 13 Abstract: LB423 Looking forward to extending the impact! #PrecisionImmunotherapy @EileenMOReilly @ciacobu @ldiaz1971 @TheVinodLab @CpcrMsk

Pembrolizumab and olaparib in HRD metastatic PDAC: the phase 2 POLAR trial @NatureMedicine doi.org/10.1038/s41591… 👏great translational study 👉subset of HRD PDAC derive prolonged benefit from PARP-ICB maintenance 🧐We need biomarker @myESMO @ASCO

A new drug is showing promise in lung and pancreatic cancers (two of the most aggressive forms of cancer) by targeting one of the most common cancer-driving mutations. Researchers at Memorial Sloan Kettering Cancer Center (MSK), including gastrointestinal medical oncologist @CentralParkWMD who led the global phase 1 clinical trial, shared results published in the @NEJM. The trial tested setidegrasib, a drug that tags and destroys the cancer-causing protein produced by the KRAS G12D mutation. This new method for targeting a long-known mutation is called a KRAS degrader. KRAS mutations are present in about 1 in 5 cancers. The G12D subtype drives about 40% of pancreatic cancers and 5% of non-small cell lung cancers. “This drug’s potential is exciting,” says Dr. Park, “because the trial results suggest that setidegrasib can not only extend life for some patients with these aggressive cancers, it also has a very good safety profile, meaning the drug was well-tolerated with side effects that can be managed quite easily." Learn more about this research: bit.ly/4lSeoJa

So @CentralParkWMD has a @NEJM and a @NatureMedicine paper on the same day! @EileenMOReilly amazing! nejm.org/doi/full/10.10… nature.com/articles/s4159…

1/n Setidegrasib the first-in-human, first-in-class, KRAS G12D-targeted protein degrader #TPD Our KRAS G12D degrader study is now published in the New England Journal of Medicine @NEJM nejm.org/doi/full/10.10… A new way to target KRAS G12D - one of the most common oncogenic drivers across cancers.

@CentralParkWMD @CatherineaOC Grateful to learn alongside you - and constantly inspired! Huge congrats Wungki, this is extraordinary.

The true joy of academic medicine is seeing your mentees grow and shine. 🌟@CatherineaOC ✨@MarcHilmi 💫 Priceless experience to work with exceptional colleagues like @CatherineaOC and @MarcHilmi - already ✨stars 💫 when they joined and continuing to push the field forward and shining through 💡🔦 Mentorship is less about shaping and more about supporting - creating space, sharing perspective and helping navigate the inevitable challenges along the way. Honestly, all you can do is maybe buy some delicious meals and snacks 🍕🍢🥘and bring them to happy hours 🍸 and 📣🙌🥳cheer them up as they go through many obstacles. I’ve been fortunate to learn from my own “Yoda” @EileenMOReilly and I try to carry that forward. Excited about what’s ahead for #sPARKlab and the next generation of investigators. Trying my best to emulate what my Yoda is doing and try to raise as many ⭐️🌟✨💫 as I can. @FiyinfoluB @AnupriyaSingha9 @schoenfeld_j @MichaelMayMD @nasca_vincenzo @jmsongmd

🤯🤯 Huge congratulations to @CentralParkWMD for two first-author papers in NEJM and Nature Medicine - on the same day! Truly extraordinary contribution to the field. Proud to be part of this @MSKCancerCenter team! @EileenMOReilly @ciacobu

Presented at #ELCC26: In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. Full trial results: nejm.org/doi/full/10.10… @myESMO

Outstanding bidirectional science and integrated clinical observations leading to deep insights in pancreas cancer - congratulations to @CentralParkWMD who led this 7 year (and ongoing) project! Very grateful to - patients, families and extended MSK team who made this happen.